A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
暂无分享,去创建一个
Gang Wang | Steven A. Rosenberg | Zelig Eshhar | Silvana Canevari | S. Rosenberg | P. Hwu | S. Canevari | J. Yang | Z. Eshhar | D. White | Clara C. Chen | Gang Wang | M. Kershaw | J. Wunderlich | L. Rogers-Freezer | S. Mavroukakis | J. Westwood | Patrick Hwu | James C. Yang | Sharon A. Mavroukakis | John R. Wunderlich | Michael H. Kershaw | Jennifer A. Westwood | Linda L. Parker | Donald E. White | Linda Rogers-Freezer | L. Parker | Linda J. Rogers-Freezer | J. A. Westwood
[1] A. Boynton,et al. Anti‐prostate specific membrane antigen designer T cells for prostate cancer therapy , 2004, The Prostate.
[2] Sanjiv S Gambhir,et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[3] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[4] A. Thor,et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.
[5] Douglas D. Taylor,et al. Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. , 2004, Gynecologic oncology.
[6] J. Mcarthur,et al. Anti-Tumor CC49-ζ CD4 T Cells Possess Both Cytolytic and Helper Functions , 2000 .
[7] M. Smyth,et al. Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.
[8] J. Blattman,et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.
[9] S. Rosenberg,et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.
[10] S. Rosenberg,et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain , 1993, The Journal of experimental medicine.
[11] Michel Sadelain,et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.
[12] V. Zurawski,et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. , 1991, Cancer research.
[13] S. Rosenberg,et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. , 2000, Human gene therapy.
[14] S. Canevari,et al. Level of anti‐mouse‐antibody response induced by bi‐specific monoclonal antibody OC/TR in ovarian‐carcinoma patients is associated with longer survival , 1999, International journal of cancer.
[15] Michel Sadelain,et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.
[16] J. da Silva,et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.
[17] Nicola Ragni,et al. HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance , 2005, Oncology.
[18] S. Ménard,et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. , 1994, European journal of cancer.
[19] M. Brenner,et al. Genetic modification of T lymphocytes for adoptive immunotherapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Hwu,et al. Dual-specific T cells combine proliferation and antitumor activity , 2002, Nature Biotechnology.
[22] S. Steinberg,et al. Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response , 1994, Cancer.
[23] Z. Eshhar,et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. , 2004, The Journal of clinical investigation.
[24] S. Ménard,et al. Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.
[25] B. Yin,et al. Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.
[26] R. Freedman,et al. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. , 1996, Cancer treatment and research.
[27] S. Rosenberg,et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. , 1995, Cancer research.
[28] S. Ménard,et al. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. , 1990, The British journal of cancer. Supplement.
[29] J. Mcarthur,et al. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. , 2000, Journal of immunotherapy.
[30] F. Thistlethwaite,et al. Engineering T cells for cancer therapy , 2005, British Journal of Cancer.
[31] S. Canevari,et al. Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. , 1998, Cancer research.
[32] J. Trapani,et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.
[33] J. Trapani,et al. Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation , 2003, The Journal of Immunology.
[34] S. Forman,et al. Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.
[35] S. Rosenberg,et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.